Protagenic Therapeutics (PTIX) and Phytanix Bio said Monday that they have agreed to combine in an all-stock deal.
Shares almost quadrupled as intraday trading volume catapulted to over 80 million from a daily average of about 460,000.
BrainStorm Cell Therapeutics (BCLI) said it has received clearance from the US Food and Drug Administration to launch a phase 3b trial of NurOwn to treat amyotrophic lateral sclerosis.
Shares jumped 18%, with intraday trading volume at over 54 million versus a daily average of roughly 178,000.
Roth Capital raised its price target on Sable Offshore (SOC) to $38 from $26 while maintaining its buy rating.
Shares rose 20% as trading volume surged to more than 5.8 million from a daily average of about 1.6 million.
Price: 11.85, Change: +8.82, Percent Change: +291.22
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。